NRXS

Neuraxis, Inc. (NRXS) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Neuraxis, Inc. is a growth-stage medical device company specializing in neuromodulation therapies. Its primary revenue-generating product is the IB-STIM device for functional abdominal pain in children. The company also recently launched the RED device for rectal expulsion testing. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 46.2% quarter-over-quarter (Q2 2025 vs. Q2 2024) and 42.3% year-to-date. Growth was driven by volume increases from insured customers and the launch of the RED device.
• Margin Compression: Gross margin decreased from 88.0% to 83.6% in Q2. This was attributed to higher discounting for patients without insurance (financial assistance programs) and expired RED inventory charges ($12,174).
• Expense Management: General and Administrative (G&A) expenses decreased 13.8% in Q2 compared to the prior year, primarily due to the absence of one-time severance and consulting costs incurred in 2024. However, YTD G&A increased slightly due to a one-time litigation settlement charge.
• Liquidity Improvement: Cash balances increased by $2.29 million during the six-month period, driven by $5.0 million in proceeds from a common stock offering and $1.0 million from warrant exercises.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months. While the company currently has a working capital surplus, it has incurred losses since inception and relies on future financing or revenue growth to sustain operations.
• Unusual Items:
  • Litigation Settlement: The company recorded a $630,568 charge (YTD) related to a $750,000 settlement of a 2019 lawsuit (Bhambhani/Rao). Payments begin in January 2026.
  • License Termination: On July 1, 2025 (subsequent event), the company terminated its license with Masimo for the NSS-2 Bridge device, recapturing trademark and patent rights for $200,000 consideration.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including ineffective approval processes, inadequate contract management, and misapplication of GAAP. Remediation efforts are ongoing.
• Outlook: Future profitability depends on securing widespread insurance coverage for the IB-STIM device and FDA clearance for new indications. The company plans to fund operations through additional equity or debt financing.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.99 million cash balance against the burn rate, given the "substantial doubt" going concern warning.
• Revenue Quality: Assess the sustainability of revenue growth given the decline in gross margins due to increased discounting for uninsured patients.
• Litigation Exposure: Confirm the status of the remaining claims in the Bhambhani/Rao lawsuit and the impact of the $750,000 settlement on future cash flows starting in 2026.
• Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting to ensure future financial statement reliability.
• Dilution Risk: Review the impact of recent equity issuances (1.5 million shares in May 2025) and outstanding warrants/options on future earnings per share.